CIA
RETA

CSat Investment Advisory’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

CSat Investment Advisory’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-55
Closed -$5K – 1011
2020
Q3 		$5K Buy
55
+6
+12% +$750 ﹤0.01% 1087
2020
Q2 		$8K Buy
+49
New +$7.45K ﹤0.01% 1077

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

CSat Investment Advisory's RETA Position: Q4 2020 in Review

CSat Investment Advisory sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2020, closing a stake of 55 shares — an estimated $5K sold.

CSat Investment Advisory first reported a position in RETA in Q2 2020 and held it in 2 quarters. The position peaked at $8K in Q2 2020. 202 funds tracked by Wall St. Rank hold RETA as of Q4 2020.

  • CSat Investment Advisory reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 55 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2020, an estimated $5K.
  • CSat Investment Advisory first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and held it in 2 quarters.
  • CSat Investment Advisory's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $8K in Q2 2020.
  • 202 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.